Enveric Biosciences报告说,抑郁症/焦虑性药物候选EB-003在临床上取得了积极的初步结果。 Enveric Biosciences reports positive preclinical results for depression/anxiety drug candidate EB-003.

Enveric Bioscience(ENVB)报告说,其主要药物候选者EB-003的临床前期安全和药理学结果令人鼓舞,其目的是治疗抑郁和焦虑等精神疾病。 Enveric Biosciences (ENVB) reported encouraging preclinical safety and pharmacology results for its lead drug candidate, EB-003, aimed at treating mental health disorders like depression and anxiety. 该化合物选择性地靶向 5-羟色胺能受体，脱靶效应最小，减少了安全问题。 The compound selectively targets serotonergic receptors with minimal off-target effects, reducing safety concerns. 尽管取得了这些积极成果,公司股票却下跌了10%以上。 Despite these positive results, the company's stock fell over 10%. Enveric计划在2025年Q3之前提交调查性新药物应用,到年底开始临床发展。 Enveric plans to file an Investigational New Drug application by Q3 2025 and begin clinical development by year-end.